TB and HIV therapeutics: Pharmacology research priorities

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Dooley, Kelly E ^a   Kim, Peter S ^b   Williams, Sharon D ^b   Hafner, Richard ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873852738     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/874083     Document Type: Review

References (57)

1. UNAIDS, The global AIDS epidemic. Global Report Fact Sheet 2010, http://www.unaids.org/en/media/unaids/contentassets/documents/factsheet/2010/ 20101123-FS-Global-em-en.pdf
2. World Health Organization, Global tuberculosis control 2011. Global TB control report 2011 WHO/HTM/TB/2011.16
3. Abdool Karim S. S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., Gengiah T., Nair G., Bamber S., Singh A., Khan M., Pienaar J., El-Sadr W., Friedland G., Abdool Karim Q., Timing of initiation of antiretroviral drugs during tuberculosis therapy. The New England Journal of Medicine 2010 362 8 697 706 2-s2.0-77349094313 10.1056/NEJMoa0905848
4. Abdool Karim S. S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., Gengiah T., Nair G., Bamber S., Singh A., Khan M., Pienaar J., El-Sadr W., Friedland G., Abdool Karim Q., Integration of antiretroviral therapy with tuberculosis treatment. The New England Journal of Medicine 2011 365 16 1492 1501 10.1056/NEJMoa1014181
5. Blanc F., Sok T., Laureillard D., Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. The New England Journal of Medicine 2011 365 1471 1481
6. Havlir D. V., Kendall M. A., Ive P., Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. The New England Journal of Medicine 2011 352 1482 1491
7. Naiker S., Conolly C., Weisner L., Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. Proceedings of the 18th Conference on Retrovirueses and Opportunistic Infections (CROI '11) 2011 650. paper #650
8. Weiner M., Benator D., Burman W., Peloquin C. A., Khan A., Vernon A., Jones B., Silva-Trigo C., Zhao Z., Hodge T., Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clinical Infectious Diseases 2005 40 10 1481 1491 2-s2.0-20944440618 10.1086/429321 (Pubitemid 40628637)
9. Niemi M., Backman J. T., Fromm M. F., Neuvonen P. J., Kivistö K. T., Pharmacokinetic interactions with rifampicin: clinical relevance. Clinical Pharmacokinetics 2003 42 9 819 850 2-s2.0-0042163137 10.2165/00003088-200342090- 00003 (Pubitemid 36995083)
10. Boulle A., Van Cutsem G., Cohen K., Hilderbrand K., Mathee S., Abrahams M., Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. Journal of the American Medical Association 2008 300 5 530 539 10.1001/jama.300.5.530
11. Manosuthi W., Sungkanuparph S., Tantanathip P., Lueangniyomkul A., Mankatitham W., Prasithsirskul W., A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases 2009 48 12 1752 1759 10.1086/599114
12. Swaminathan S., Padmapriyadarsini C., Venkatesan P., Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clinical Infectious Diseases 2011 53 7 716 724
13. Cohen K., Grant A., Dandara C., McIlleron H., Pemba L., Fielding K., Charalombous S., Churchyard G., Smith P., Maartens G., Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antiviral Therapy 2009 14 5 687 695 2-s2.0-69849091857
14. Ngaimisi E., Mugusi S., Minzi O., Sasi P., Riedel K. D., Suda A., Ueda N., Janabi M., Mugusi F., Haefeli W. E., Bertilsson L., Burhenne J., Aklillu E., Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clinical Pharmacology and Therapeutics 2011 90 406 413 2-s2.0-79960890224 10.1038/clpt.2011.129
15. Acosta E. P., Kendall M. A., Gerber J. G., Alston-Smith B., Koletar S. L., Zolopa A. R., Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrobial Agents and Chemotherapy 2007 51 9 3104 3110 10.1128/AAC.00341-07 (Pubitemid 350067515)
16. Burger D. M., Agarwala S., Child M., Been-Tiktak A., Wang Y., Bertz R., Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrobial Agents and Chemotherapy 2006 50 10 3336 3342 10.1128/AAC.00461-06 (Pubitemid 44527507)
17. Justesen U. S., Andersen A. B., Klitgaard N. A., Brosen K., Gerstoft J., Pedersen C., Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clinical Infectious Diseases 2004 38 3 426 429 10.1086/380794 (Pubitemid 38200123)
18. LaPorte C., Colbers E., Bertz R., Vonchek D., Wikstrom K., Boeree M., Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrobial Agents and Chemotherapy 2004 48 5 1553 1560 10.1128/AAC.48.5.1553-1560.2004 (Pubitemid 38544359)
19. Schmitt C., Riek M., Winters K., Schutz M., Grange S., Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Archives of Drug Information 2009 2 1 8 16 10.1111/j.1753-5174.2009.00017.x
20. Haas D. W., Koletar S. L., Laughlin L., Kendall M. A., Suckow C., Gerber J. G., Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. Journal of Acquired Immune Deficiency Syndromes 2009 50 3 290 293 10.1097/QAI.0b013e318189a7df
21. Nijland H. M., L'homme R. F., Rongen G. A., van Uden P., van Crevel R., Boeree M. J., High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008 22 8 931 935 10.1097/QAD.0b013e3282faa71e (Pubitemid 351652243)
22. Loeliger A., Suthar A. B., Ripin D., Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? The International Journal of Tuberculosis and Lung Disease 2012 16 1 6 15
23. Trapnell C. B., Jamis-Dow C., Klecker R. W., Collins J. M., Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrobial Agents and Chemotherapy 1997 41 5 924 926 2-s2.0-0030999969 (Pubitemid 27194161)
24. Cato A. III, Cavanaugh J., Shi H., Hsu A., Leonard J., Granneman R., The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clinical Pharmacology and Therapeutics 1998 63 4 414 421 2-s2.0-0031900568 10.1016/S0009-9236(98)90036-4 (Pubitemid 28214964)
25. Decloedt E. H., McIlleron H., Smith P., Merry C., Orrell C., Maartens G., Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrobial Agents and Chemotherapy 2011 55 7 3195 3200 2-s2.0-79959215519 10.1128/AAC.01598-10
26. Wenning L. A., Hanley W. D., Brainard D. M., Petry A. S., Ghosh K., Jin B., Mangin E., Marbury T. C., Berg J. K., Chodakewitz J. A., Stone J. A., Gottesdiener K. M., Wagner J. A., Iwamoto M., Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrobial Agents and Chemotherapy 2009 53 7 2852 2856 2-s2.0-66949149605 10.1128/AAC.01468-08
27. Ananworanich J., Gorowara M., Avihingsanon A., Pharmacokinetic and short-term virologic response of low dose raltegravir 400mg once daily maintenance therapy. Antimicrobial Agents and Chemotherapy 2012 56 4 1892 1898
28. Eron J. J. Jr., Rockstroh J. K., Reynes J., Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. The Lancet Infectious Diseases 2011 59 3 229 235
29. Vernon A., Burman W., Benator D., Khan A., Bozeman L., Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. The Lancet 1999 353 9167 1843 1847 2-s2.0-0033614603 10.1016/S0140-6736(98)11467-8 (Pubitemid 29251017)
30. Weiner M., Burman W., Vernon A., Benator D., Peloquin C. A., Khan A., Weis S., King B., Shah N., Hodge T., Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. American Journal of Respiratory and Critical Care Medicine 2003 167 10 1341 1347 2-s2.0-0037614780 10.1164/rccm.200208-951OC (Pubitemid 36609717)
31. Srivastava S., Sherman C., Meek C., Leff R., Gumbo T., Pharmacokinetic mismatch does not lead to emergence of isoniazid-or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemotherapy 2011 55 11 5085 5089
32. Peloquin C. A., Pharmacokinetic mismatch of tuberculosis drugs. Antimicrob Agents Chemotherapy 2012 56 3, article 1666
33. Dooley K. E., Bliven-Sizemore E. E., Weiner M., Safety and pharmacokinetics of escalating daily doses of rifapentine, an anti-tuberculosis drug, in healthy volunteers. Clinical Pharmacology & Therapeutics 2012 91 5 881 888
34. Sterling T. R., Villarino M. E., Borisov A. S., Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England Journal of Medicine 2011 365 23 2155 2166
35. Desta Z., Soukhova N. V., Flockhart D. A., Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrobial Agents and Chemotherapy 2001 45 2 382 392 2-s2.0-0035144768 10.1128/AAC.45.2.382-392.2001 (Pubitemid 32105271)
36. Diacon A. H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., Pistorius C., Krause R., Bogoshi M., Churchyard G., Venter A., Allen J., Palomino J. C., De Marez T., Van Heeswijk R. P. G., Lounis N., Meyvisch P., Verbeeck J., Parys W., De Beule K., Andries K., Mc Neeley D. F., The diarylquinoline TMC207 for multidrug-resistant tuberculosis. The New England Journal of Medicine 2009 360 23 2397 2405 2-s2.0-66649090346 10.1056/NEJMoa0808427
37. McNeeley C. F., TMC207 Team, Diacon A. H., TMC-207 versus placebo plus OBT for the treatment of MDR-TB: a prospective clinical trial. Proceedings of the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease November 2010 Berlin, Germany
38. McNeeley D. F., Diacon A. H., TMC207: Recent advances in development. 2006, http://www.kaisernetwork.org/health-cast/uploaded-files/18-2-MCNEELEY- DAVID.pdf
39. Dooley K. E., Park J. G., Swindells S., Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267. Journal of Acquired Immune Deficiency Syndromes 2012 59 5 455 462
40. Mesens N., Verbeeck J., Rouan M. C., De Beule K., Vanparys P., Elucidating the role of M2 in the preclinical safety profile of TMC207. Proceedings of the 38th Union World Conference on Lung Health Cape Town, South Africa. Abstract PS-71291-11, November 2007
41. van Heeswijk R., Vandevoorde A., Meyvisch P., DeMarez T., McNeeley D., Hoetelmans R., The effect of nevirapine on the pharmacokinetics of TMC207, an investigational antimycobacterial agent, in HIV-1-infected subjects. Proceedings of the 6th IAS Conference on HIV Pathogenesis, Prevention, and Treatment 2011 Rome, Italy
42. van Heeswijk R., Vandevoorde A., Meyvisch P., The effect of lopinavir/ritonavir on the pharmacokinetics of TMC207, an investigational antimycobacterial agent. Proceedings of the 18th International AIDS Conference Vienna, Austria. Abstract WEPE0097, 2010
43. Stover C. K., Warrener P., VanDevanter D. R., Sherman D. R., Arain T. M., Langhorne M. H., Anderson S. W., Towell J. A., Yuan Y., McMurray D. N., Kreiswirth B. N., Barry C. E., Baker W. R., A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000 405 6789 962 966 2-s2.0-0034702247 10.1038/35016103 (Pubitemid 30435054)
44. Nuermberger E., Tyagi S., Tasneen R., Williams K. N., Almeida D., Rosenthal I., Grosset J. H., Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy 2008 52 4 1522 1524 2-s2.0-42049101775 10.1128/AAC.00074-08 (Pubitemid 351522025)
45. Diacon A. H., Dawson R., Hanekom M., Narunsky K., Maritz S. J., Venter A., Donald P. R., Niekerk C. V., Whitney K., Rouse D. J., Laurenzi M. W., Ginsberg A. M., Spigelman M. K., Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrobial Agents and Chemotherapy 2010 54 8 3402 3407 2-s2.0-77955350759 10.1128/AAC.01354-09
46. Jia L., Tomaszewski J. E., Hanrahan C., Coward L., Noker P., Gorman G., Nikonenko B., Protopopova M., Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. British Journal of Pharmacology 2005 144 1 80 87 2-s2.0-13244283085 10.1038/sj.bjp.0705984 (Pubitemid 40192564)
47. Tahlan K., Wilson R., Kastrinsky D. B., SQ109 targets mmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2012 56 4 1797 1809
48. Chen P., Gearhart J., Protopopova M., Einck L., Nacy C. A., Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. Journal of Antimicrobial Chemotherapy 2006 58 2 332 337 2-s2.0-33748040742 10.1093/jac/dkl227 (Pubitemid 44294944)
49. Jia L., Noker P. E., Coward L., Gorman G. S., Protopopova M., Tomaszewski J. E., Interspecies pharmacokinetics and in vitro metabolism of SQ109. British Journal of Pharmacology 2006 147 5 476 485 2-s2.0-33644828189 10.1038/sj.bjp.0706650 (Pubitemid 43355045)
50. Wallis R. S., Jakubiec W., Kumar V., Bedarida G., Silvia A., Paige D., Zhu T., Mitton-Fry M., Ladutko L., Campbell S., Miller P. F., Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrobial Agents and Chemotherapy 2011 55 2 567 574 2-s2.0-78751693374 10.1128/AAC.01179-10
51. Kumar V., Liu J., Wallis R. S., Population PK-PD modeling of phase 1 data of PNU-100480 to guide doses for phase 2a study. Proceedings of the 3rd International Workshop on Clinical Pharmacology of TB Drugs September 2010 Boston, Mass, USA
52. World Health Organization, Rapid advice: Treatment of tuberculosis in children. WHO/HTM/TB 2010 2010.13
53. van den Anker J. N., Schwab M., Kearns G. L., Developmental pharmacokinetics. Handbook of Experimental Pharmacology Journal 2011 205 51 75
54. McIlleron H., Ren Y., Nuttall J., Fairlie L., Rabie H., Cotton M., Eley B., Meyers T., Smith P. J., Merry C., Maartens G., Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antiviral Therapy 2011 16 3 417 421 2-s2.0-79959450135 10.3851/IMP1757
55. Oudijk J. M., McIlleron H., Mulenga V., PKs of nevirapine in young children during combined ART and rifampicin-containing anti-TB treatment. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention Cape Town, South Africa. Abstract LBPEB10, July 2009
56. Elsherbiny D., Ren Y., McIlleron H., Maartens G., Simonsson U. S. H., Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. European Journal of Clinical Pharmacology 2010 66 10 1017 1023 2-s2.0-77957686866 10.1007/s00228-010-0847-9
57. Ren Y., Nuttall J. J. C., Egbers C., Eley B. S., Meyers T. M., Smith P. J., Maartens G., McIlleron H. M., Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. Journal of Acquired Immune Deficiency Syndromes 2008 47 5 566 569 2-s2.0-41149107340 10.1097/QAI.0b013e3181642257 (Pubitemid 351442016)